Our experiments using a tumor xenograft model showed that ANT2-knockdown-induced sensitization to TRAIL also occurs in vivo and that combination therapy with ANT2 shRNA and TRAIL very efficiently inhibits tumor growth. This evidence concerns the gene TNFSF10 and neoplasm.